INTRODUCTION

Corticotropin-releasing factor (CRF) was discovered in 1981 by Vale and colleagues at the Salk Institute (Vale et al., 1981). Its existence had been hypothesized for many years prior to the 1981 paper characterizing the amino acid sequence of the peptide. Since then, the importance of CRF family of peptides and receptors in stress has steadily emerged. Extensive investigation has demonstrated that CRF is critical in regulating the hypothalamic-pituitary-adrenal (HPA) axis and in integrating endocrine, autonomic, and behavioral responses to stressors (Perrin and Vale, 1999).

The vital role of the corticotropin-releasing factor (CRF) peptide family in the brain in coordinating response to stress has been extensively documented. The effects of CRF are mediated by two G-protein-coupled receptors, type 1 and type 2 CRF receptors (CRF1 and CRF2). While the functional role of CRF1 in hormonal and behavioral adaptation to stress is well-known, the physiological significance of CRF2 remains to be fully appreciated. Accumulating evidence has indicated that CRF2 and its selective ligands including urocortin 3 (Ucn 3) are important molecular mediators in regulating energy balance. Ucn 3 is the latest addition of the CRF family of peptides and is highly selective for CRF2. Recent studies have shown that central Ucn 3 is important in a number of homeostatic functions including suppression of feeding, regulation of blood glucose levels, and thermoregulation, thus reinforcing the functional role of central CRF2 in metabolic regulation. The brain loci that mediate the central effects of Ucn 3 remain to be fully determined. Anatomical and functional evidence has suggested that the ventromedial hypothalamus (VMH), where CRF2 is prominently expressed, appears to be instrumental in mediating the effects of Ucn 3 on energy balance, permitting Ucn 3-mediated modulation of feeding and glycemic control. Thus, the Ucn 3/VMH CRF2 system is an important neural pathway in the regulation of energy homeostasis and potentially plays a critical role in energy adaptation in response to metabolic perturbations and stress to maintain energy balance.

Keywords: CRF, Ucn 3, VMH, energy balance, feeding, glucose
CORTICOTROPIN-RELEASING FACTOR RECEPTORS

Two receptors have been identified for CRF: type 1 and type 2 CRF receptors (CRF1 and CRF2), and amino acid sequence analysis has shown that the two receptors share approximately 70% homology (Perrin and Vale, 1999; Bale and Vale, 2004). Both CRF1 and CRF2 are G-protein-coupled receptors with seven transmembrane domains. These receptors signal predominantly through increased cAMP production, but additional signaling pathways including Ca2+, mitogen-activated protein kinase (MAPK), phospholipase C, protein kinase C, and ion channels have also been shown to couple to CRFRs (Kiang, 1997; Grammatopoulos, 2000; Brar et al., 2002). The two receptors differ significantly in their binding affinity for CRF peptides and anatomical distribution within the central nervous system (Chalmers et al., 1995; Van Pett et al., 2005; Hou and Hsueh, 2001; Lewis et al., 2001). Biochemical studies have shown that CRF binds CRF1 with high affinity while showing modest affinity for CRF2 (Bale and Vale, 2004). Ucn 1 binds both CRF1 and CRF2 with equally high affinity while Ucn 2 and Ucn 3 demonstrate preferential specificity for CRF2. However, while Ucn 2 may bind and stimulate CRF1 at high, pharmacological concentrations (Reyes et al., 2001), Ucn 3 is highly selective to CRF2 and displays minimal affinity for CRF1 (Hou and Hsueh, 2001; Lewis et al., 2001).

A circulating protein has been identified that binds CRF. It has been suggested that the function of CRF binding protein (CRFBP) is mainly to sequester CRF to reduce its HPA axis stimulation. Levels of CRFBF are elevated in pregnancy to dampen the negative effect of stress responses on the developing fetus (Goland, 1986). In addition to CRFBP, a splice variant of CRF1 has been identified that contains only the extracellular domain of the receptor and shown to circulate, bind, and sequester CRF as well (Iben et al., 1997; Chen et al., 2005). This splice variant also binds Ucn 1 but has very low affinity for Ucn 2 and Ucn 3 (Chen et al., 2005).

Anatomical mapping studies have demonstrated that CRF1 and CRF2 have distinct distributions in the brain. CRF1 has a wide distribution throughout the brain with high density in the medial septal area, amygdala, and cerebellum (Chalmers et al., 1995; Van Pett et al., 2005). CRF1 has three major variants that differ in their N-terminal domains: CRF1A, CRF1B, and CRF1C. In murine brains, CRF2A is predominantly expressed in the hypothalamus, lateral septum (LS), and dorsal raphe (Chalmers et al., 1995; Van Pett et al., 2005). CRF2A is found predominantly in the periphery, including in skeletal muscle, the gastrointestinal tract, and the heart (Kanno, 1999; Wiley and Davenport, 2004; Porcher et al., 2005; Tache and Bonast, 2007). CRF2B is found only in the human brain (Kostich et al., 1998).

The function of CRF1 has been closely associated with the stress response, including the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary and behavioral adaptation to stressors (Bale and Vale, 2004). However, is less defined. Functional studies have shown this receptor is involved in an array of homeostatic regulations, with most of its actions regulating energy balance by modulating feeding, blood glucose levels, and energy expenditure. This review will focus on recent advances in the understanding of the physiological role of CRF1 and CRF2 in the brain, particularly in the hypothalamus, in the regulation of energy balance.

CRF IN ENERGY HOMEOSTASIS

Loss-of-function studies with CRF2 null mice and pharmacological studies with CRF2 agonists both suggest that endogenous CRF2 plays a physiological role in energy balance. Evidence from several studies that examined ingestive behavior of CRF2 null mice showed that endogenous CRF2 is required for the anorectic effect of CRF peptide and is involved in control of the meal size during active phase of eating and following acute exposure to the stress (Bale et al., 2000; Coste et al., 2000; Pellemounter et al., 2000; Tabarin et al., 2007). Similarly, infusion of antiserum oligonucleotides to CRF2 mRNA attenuates both CRF and Ucn 1-induced hypophagia and corticosterone secretion (Smagin et al., 1998). Furthermore, CRF2 deletion protects mice from high-fat diet-induced insulin resistance and glucose intolerance (Bale et al., 2003). Taken together, it is clear that CRF2 is responsible for mediating the effect of CRF family peptides on the suppression of feeding and is involved in corticosterone secretion and glucose homeostasis.

In addition to feeding, CRF2 is involved in regulating energy expenditure. CRF2 knockout (KO) mice have more active metabolism and lose heat faster than wildtype (WT) mice (Carlin et al., 2006), suggesting an exaggerated level of sympathetic activity. Moreover, CRF2 KO mice have higher brown adipose tissue (BAT) temperature and, when given a choice between room temperature and warm areas, prefer warmer areas more than WT mice (Carlin et al., 2006). The KO mice also have higher oxygen consumption and carbon dioxide production and reduced respiratory exchange rate (Carlin et al., 2006), indicating a preference in fatty acid oxidation over carbohydrate utilization in the KO mice. It was suggested that a lack of functional CRF2 leads to elevated CRF1 activity, which consequently increases sympatho-adrenal nervous system (SNS) activity to promote lipolysis (Carlin et al., 2006). This hypothesis appears to disagree with pharmacological studies, as activation of central CRF2 (discussed below), in most cases, results in increased SNS activity. This apparent discrepancy may result from a number of possibilities including compensatory mechanisms due to total body KO of the receptor as compared to acute, local stimulation of the receptor in the brain. Obviously more studies are needed to further elucidate this issue.

Leptin, a hormone secreted by adipocytes, is a potent appetite suppressant (Uchida et al., 1996; Zingman, 2003). A number of studies suggest that its effect on feeding may involve the CRF receptor system. Though leptin treatment greatly decreases food intake, when co-administered with a non-selective CRF receptor antagonist, food intake remains at a nearly normal level (Gardner et al., 1998), suggesting the CRF system is a downstream target of leptin in the brain. However, this notion was recently challenged by a study (Harris, 2010) demonstrating that CRF2 is not essential for the effects of leptin on energy balance, including feeding and body weight regulation. Again this discrepancy may be due to the nature of global CRF-KO, which potentially results in functional compensation such as exaggerated CRF1 activity in these mice (Carlin et al., 2006). Therefore, central or specific brain area deletions of CRF2 may be necessary to further evaluate the interaction of leptin and the CRF system in the brain.
UROCORTIN 3

ANATOMICAL LOCATION OF Ucn 3

Urocortin 3 is found both in the periphery and in the brain. In the periphery, it is expressed in the digestive tract, muscle, thyroid and adrenal glands, pancreas, heart, spleen, and skin (Hsu and Hsieh, 2001; Lewis et al., 2001). In the brain, neurons expressing Ucn 3 are concentrated in the medial amygdala (MeA) and hypothalamus (Lewis et al., 2001; Li et al., 2002). In the hypothalamus, the major Ucn 3 cell population is near the rostral perifornical hypothalamic area (FPFa; Li et al., 2002). Specifically, Ucn 3-positive cells are gathered around the fornix lateral to the paraventricular nucleus of the hypothalamic area (PVH). This group extends rostrally and stays close to the fornix into the posterior part of the bed nucleus of the stria terminalis (pBNST) and medially into the anterior parvicellular part of the PVH (PVHap). A recent study has elucidated anatomical heterogeneity within this hypothalamic Ucn 3 cell population, as neurons of the rostral part (PVHap/pBNST) project to the ventromedial hypothalamic area (VMH), and those of the caudal part, residing in the rostral perifornical hypothalamic area (rPFH), projects to the LS (Chen et al., 2011). A second group of Ucn 3-positive cells is found in the median preoptic nucleus (MnPO; Li et al., 2002). In the forebrain, prominent Ucn 3 nerve fibers and terminals are found in the VMH, LS, MeA, and BNST (Li et al., 2002). These areas also express high levels of CRF2 (Chalmers et al., 1995; Van Pett et al., 2000). This overlap of Ucn 3 and CRF2 distribution and the high affinity of the peptide for the receptor strongly suggest that Ucn 3 is an endogenous ligand for CRF2 in these brain areas.

METABOLIC EFFECTS OF Ucn 3

All 3 Ucns bind CRF2, and may each be responsible for some of the receptor’s energy homeostatic effects. However, Ucn 3 alone has myriad metabolic effects.

Feeding

Central administration, KO, and overexpression studies reveal a role of Ucn 3 in the regulation of feeding. When directly infused into the lateral ventricles, Ucn 3 decreases nocturnal food and water intake in a dose dependent manner, primarily due to decreased meal frequency, and this effect was eliminated with concomitant CRF2 antagonist treatment (Fekete et al., 2007). The anorectic effect of Ucn 3 is not due to distaste for food, as no current taste aversion develops (Fekete et al., 2007). Consistent with pharmacological evidence, genetic Ucn 3 deficiency appears to lead to overeating. Though Ucn 3 KO mice have similar body weights to WT animals, KO mice eat more and have increased accumulated food intake. Similar to CRF2-null mice, Ucn 3 KO mice exhibit elevated nocturnal feeding, when greatest spontaneous food intake naturally occurs (Cho et al., 2012). Taken together, it is clear that Ucn 3 in the brain functions as a potent anorectic agent. However, a study that used genetic overexpression of Ucn 3 challenged this notion. Under regular chow-fed condition, mice with overexpression of Ucn 3 (Ucn3+) have higher body mass-adjusted food intake than WT and are heavier than WT controls due to increased lean body mass (Jamieson et al., 2011). On the other hand, Ucn3– mice do not gain as much weight as WT mice when fed with a high-fat diet (Jamieson et al., 2011). This result seems to be in line with the notion of Ucn 3 as an anorectic agent. The discrepancy between different mouse models can be due to a number of possibilities including the ramification of Ucn 3 overexpression both in the brain as well as in the periphery.

A temporally and spatially controlled viral approach to overexpress Ucn 3 in the rPFH shows that Ucn 3 in the rPFH does not modulate food intake (Kuperman et al., 2010), as mice with Ucn 3 overexpression in the rPFH ingest similar amount of food as control mice (Kuperman et al., 2010). The rPFH-specific Ucn 3-overexpressing mice show a trend toward being heavier, but retain the same fat–lean mass percentages as control mice (Kuperman et al., 2010). As mentioned above, Ucn 3 cells in the rPFH project mainly to the LS with minimal projection to the VMH. Therefore, it is reasonable to assume that CRF2 in the LS will be overstimulated in this mouse model. Interestingly, a number of studies have shown that CRF2 in the LS is involved in suppression of food intake (Wang and Kotz, 2002; Bakshi et al., 2007). Currently, it is unclear as to why overexpression of Ucn 3 in the rPFH fails to suppress feeding. The expression of CRF2 receptor has been shown to be subject to ligand-induced receptor down-regulation (Babadan-Diehl et al., 1996; Ogihara-Abdalli et al., 1997). It is conceivable that chronic elevated Ucn 3 input to the LS in Ucn 3 rPFH overexpression mice may lead to alteration in CRF2 expression and consequently reduced response to Ucn 3 stimulation in the LS. Thus, it is possible that acute stimulation of CRF2 in the LS suppresses feeding, but chronic stimulation of CRF2 in the LS in mice with Ucn 3 overexpression in the rPFH may lead to negative feedback to balance the effect of CRF2 in feeding. Clearly, more studies are needed to elucidate the effect of Ucn 3 overexpression in the regulation of food intake. In addition to Ucn 3, Ucn 1 neurons in the midbrain Edinger–Westphal nucleus have been shown to innervate the LS (Koizic et al., 1998; Rittenhouse et al., 1999). Therefore, both Ucn 1 and 3 may contribute to the effect of CRF2 on feeding in the LS.

The mechanism of Ucn 3-induced anorexia has not been directly studied. Central administration of CRF2 agonists, including Ucn 3, have been shown to inhibit gastric emptying (Martinez et al., 2004; Stengel and Szabo, 2005), and elevate blood glucose levels (Jamieson et al., 2006; Chen et al., 2010). Both reduced gut motility and hyperglycemia have been shown to induce satiation and reduce feeding (Ritter, 2004; Cummings and Overtur, 2007; Wolfgang et al., 2007; Cha et al., 2008). Therefore, multiple mechanisms are potentially involved in mediating the anorectic effect of Ucn 3 in the brain.

Energy homeostasis

Similarly to CRF2, Ucn 3 is also involved in energy expenditure. Central administration of Ucn 3 increases motor activity (Ohata and Shibasaki, 2004). Similarly, transgenic Ucn 3 overexpression mice (Ucn3+) have an increased respiratory exchange ratio and increased motor activity in their home cages (Jamieson et al., 2011). Furthermore, mice with Ucn 3 overexpressed in the rPFH had an increased respiratory exchange ratio and elevated heat production (Kuperman et al., 2010). This is consistent with the notion that Ucn 3 is involved in SNS activity and energy homeostasis. Ucn 3 knockout mice, on the other hand, do not show the same pattern; there are no differences in oxygen consumption, heat...
production, or activity levels (Chao et al., 2012). Therefore, KO of Ucn 3 in specific brain areas may provide better insight into the role of specific populations of Ucn 3 cells in the brain in energy expenditure.

Glucose homeostasis
Several studies have revealed a complex role of Ucn 3 in glucose homeostasis. Though adult Ucn 3 KO mice fed a chow diet show no differences in glucose tolerance and insulin sensitivity compared to WT mice (Li et al., 2007), Ucn 3 KO mice have lower basal insulin levels and show a greater rebound in blood glucose levels after the initial hypoglycemia during an insulin tolerance test (Li et al., 2007; Chao et al., 2012). Furthermore, under high-fat diet feeding, adult KO mice are more metabolically resilient. The Ucn 3 KO mice have lower plasma insulin and blood glucose concentrations than WT mice, remain sensitive to insulin and do not develop glucose intolerance and liver steatosis with the same frequency of WT mice (Li et al., 2007). Moreover, aged KO mice show better glucose homeostasis than age-matched WT mice (Li et al., 2007). Overall, Ucn 3 deficiency appears to protect the mice from metabolic disorders caused by high-fat feeding. It is noteworthy that Ucn 3 is expressed in pancreatic β cells and has been shown to play a critical role as a local regulator in insulin secretion (Li et al., 2003). Thus, it is likely that Ucn 3 in both the brain and in the periphery, especially in the pancreas, contributes to the phenotypes observed in Ucn 3 null mice.

On the other hand, Ucn3+ transgenic mice also appear to be protected against excessive metabolic challenge, having decreased fed and fasting blood glucose levels and increased tolerance to glucose when challenged in a glucose tolerance test (Jamieson et al., 2011). Fasting insulin levels in Ucn3+ mice are also lower than that in WT mice, though an insulin tolerance test shows no differences in insulin sensitivity (Jamieson et al., 2011). When challenged with a high-fat diet, Ucn3+ mice fare better than the WT littermates, maintaining normal body weight and low blood glucose levels, but display comparable insulin sensitivity to the WT control mice (Jamieson et al., 2011). Though Ucn3+ mice show improved glucose homeostasis and insulin sensitivity, overexpression of Ucn 3 in the rpHF produces the opposite effect; rpHF Ucn 3 overexpressing mice show reduced insulin sensitivity and increases basal insulin levels, however they show no difference in glucose tolerance (Kuperman et al., 2010).

While genetic KO of Ucn 3 appears to have metabolic protective qualities, the effect of Ucn 3 overexpression is unclear. Full body overexpression of Ucn 3 seems protective, while targeted overexpression within the rpHF appears metabolically detrimental. Interestingly, Ucn3+ mice have lower fasting blood glucose levels and higher energy intake under basal conditions (Jamieson et al., 2011). As stated earlier, CRF2 is expressed abundantly in a number of peripheral tissues including skeletal muscle (Perrin et al., 1995; Stenzel et al., 1995; Wiley and Davenport, 2004; Forchser et al., 2005; Supperman et al., 2011). Stimulation of muscle CRF2 has been shown to promote thermogenesis (Solinas et al., 2006). Moreover, muscle CRF2 is involved in regulating skeletal muscle mass (Hinkle et al., 2003) and consistent with this notion, Ucn3+ mice have increased muscle mass (Jamieson et al., 2011). Thus, it is conceivable that the improved glucose homeostasis of Ucn3+ mice is due, at least in part, to stimulation of muscle CRF2 by ectopic overexpression of Ucn 3 in the periphery.

Thermoregulation
Functional studies have shown that Ucn 3 is involved in thermoregulation, potentially acting on brown fat. It was found that Ucn 3 induced a significant increase in body temperature, from 37.2 to 38.6°C (99.0 to 101.5°F), when injected into the lateral ventricles of rats (Telegdy et al., 2006). Temperature gradually decreased after peaking 2 h after Ucn 3 administration, but remained significantly elevated for a total of 4 h (Telegdy et al., 2006). Moreover, pretreating animals with CRF2, but not CRF1, antagonists completely blocked Ucn 3-induced hyperthermia, indicating that the pyrogenic action of Ucn 3 is mediated by CRF2 (Telegdy and Adamik, 2008). Noradrenalphensone, a cyclooxygenase inhibitor, simultaneously applied with Ucn 3 also prevented the temperature increase and also attenuated the increase when administered 30 min after Ucn 3 treatment (Telegdy et al., 2006). This indicates that the arachidonic acid cascade forming prostaglandin is a downstream target of central Ucn 3 and CRF2 system in thermoregulation. Currently, the brain loci that may mediate the effect of Ucn 3 in body temperature remain elusive. The MnPO is known to be a center for thermoregulation and expresses high concentrations of the prostaglandin receptor EP3 (Morrison et al., 2008). It has been shown that prostaglandins may play an important role in the MnPO through EP3 to regulate body temperature (Morrison et al., 2008). Furthermore, the presence of a group of Ucn 3 cells in the MnPO (Li et al., 2002) suggests that Ucn 3 might be involved in MnPO mediates pyrogenic effects.

REGULATION OF Ucn 3 EXPRESSION IN THE BRAIN
The expression of Ucn 3 in the brain has been determined in a number of stress paradigms and metabolic challenges. It was found that restraint stress rapidly elevates Ucn 3 gene expression in the MeA and that the elevated Ucn 3 mRNA levels return to basal levels 4 h after the stress (Jamieson et al., 2006). Restraint stress also increases Ucn 3 mRNA levels in the rpHFA but with a slower time course compared to that of the MeA (Yemini et al., 2004; Jamieson et al., 2006). Adrenalectomy greatly elevates Ucn 3 expression in the rpHFA, while corticosterone replacement returns the expression to a basal level (Jamieson et al., 2006). Adrenalectomy greatly elevates Ucn 3 expression in the rpHFA, while corticosterone replacement returns the expression to a basal level (Jamieson et al., 2006). This result indicates that corticosterone may be involved in stress-mediated Ucn 3 gene expression in the rpHFA. Hemorrhage decreases Ucn 3 expression in the MeA after 30 min, and 48 h of food deprivation also decreases Ucn 3 expression in the MeA (Jamieson et al., 2006).

The expression of Ucn 3 has also been examined in genetically obese rodent models. Food deprivation increases Ucn 3 mRNA expression in the dorsal part of the medial amygdala (MeD) in obese Fa/Fa Zucker rats and has no effect on Ucn 3 expression in the rpHFA (Poulin et al., 2012). In contrast, lean Fa/Fa rats show increased Ucn 3 expression in the rpHFA but not the MeD after food deprivation (Poulin et al., 2012). Ucn 3 mRNA expression returns to normal after 24 h of refeeding (Poulin et al., 2012). In ob/ob obese mice, Ucn 3 expression is significantly reduced in the MeA (Figure 1). Li and Vale, 2003), and leptin treatment reverses Ucn 3 expression in this area. Interestingly, pair-feeding in ob/ob mice
failed to modulate Ucn 3 expression in the MeA. These results indicate that Ucn 3 expression in the MeA is regulated by leptin. Taken together, these studies further support the notion that endogenous Ucn 3 in the brain is sensitive to metabolic signals and energy status and potentially plays an important role in regulating energy homeostasis.

THE VENTROMEDIAL HYPOTHALAMUS

The anatomical distribution of CRF2 in the brain has provided important insight into possible areas that mediate the effects of CRF2 in energy balance. The VMH has received significant attention due to its abundant expression of CRF2 and well-known role in regulating energy homeostasis, feeding, and blood glucose levels.

The VMH is parceled on cytoarchitectonic grounds into three major divisions: dorsomedial (VMHdm), central, and the ventrolateral (VMHvl) parts (Gurdjian, 1927). The VMH volume is larger in males compared with females, and this difference is largely accounted for by the VMHvl, which in females is significantly smaller than that in males (Dugger et al., 2007). Further, VMHvl in female rats express higher levels of estrogen receptors than that in males, and has been shown to play a critical role in regulating lordosis behavior in females (Flanagan-Cato, 2011) and aggressiveness in males (Lin et al., 2011).

The VMH has long been considered a critical brain area in the regulation of energy homeostasis. Lesion of the VMH results in hyperphagia, hyperinsulinemia, reduction of SNS activity, increase of fat mass, and reduction of energy expenditure that ultimately leads to storage of excess of energy and obesity (Bernardis and Frohman, 1971; Inoue et al., 1977; Cox and Powley, 1981; Niijima et al., 1984; Sakaguchi et al., 1988; Ruffin and Nicolaides, 1999, King, 2006). Conversely, stimulation of the VMH results in predominantly opposite phenotypes including induction of satiety, increase in SNS activity, lipolysis, and thermogenesis (King, 2006). In recent years, the importance of the VMH in energy homeostasis has been further ascertained with the aid of improved molecular tools and mouse genetics (Stornon et al., 2003, King, 2006, Chao et al., 2012). For example, mice with VMH-specific deletion of a number of genes including the leptin receptor (Dhillon et al., 2006; Bingham et al., 2008), estrogen receptor $\alpha$ (Musatov et al., 2006, 2007), and vesicular glutamate transporter-2 (VGLUT2; Tong et al., 2007) result in a number of abnormalities such as increased feeding, reduced energy expenditure, impaired glucose homeostatic regulation, and obesity. Moreover, mice bearing a deletion of steroidogenic factor 1 (SF1), a transcription factor involved in steroidsynthesis that is highly enriched in the VMH, show similar phenotypes in energy homeostasis and are obese (Luo et al., 1994; Sadovsky et al., 1995; Shinoda et al., 1995).

EXPRESSION OF CRF2 IN THE VMH

The VMH is one of the brain areas with prominent CRF2 expression (Chalmers et al., 1995; Van Pett et al., 2000). The expression is
Chen et al. Central CRF2 in energy homeostasis

Concentrated in the dorsomedial part of the nucleus with decreasing density toward the ventrolateral division of the VMH. The expression of CRF2 in the VMH has been shown to be sensitive to energy status and stress. For example, leptin injection increases and fasting decreases CRF2 expression in the VMH and ob/ob mice or Fa/Fa Zucker rats have lower CRF2 in the VMH compared to WT controls (Richard et al., 1996; Makino et al., 1998, 1999; Nishiyama et al., 1999). Furthermore, restraint stress and glucocorticoids increase CRF2 levels in the VMH (Makino et al., 1998, 1999). Thus, these data support the notion that CRF2 in the VMH is important in regulating energy balance.

Currently, detailed neurochemical phenotypes of CRF2-positive cells within the VMH remain unclear. Several proteins have been found to be expressed in the VMH including SF1, pituitary adenylate cyclase-activating polypeptide, the leptin receptor, and VGLUT2 (Fei et al., 1997; Elmquist et al., 1998; Ziegler et al., 2002; Segal et al., 2005; Kurrasch et al., 2007). It has been shown that CRF2 extensively colocalizes with VGLUT2 in the VMH (Chen et al., 2010). VGLUT2 mediates glutamate uptake into synaptic vesicles of excitatory neurons (Freemau et al., 2001; Herzig et al., 2001; Takamori et al., 2001) and has been used extensively as a marker for excitatory glutamatergic neurons. The colocalization of CRF2 and VGLUT2 suggests that CRF2 is expressed predominantly in excitatory neurons in the VMH. As mentioned above, SF1 is a nuclear receptor that regulates the transcription of key genes involved in sexual development and reproduction (Parker et al., 2002). In adults, SF1 expression is specifically confined to the VMH (Parker et al., 2002). In SF1 null mice, CRF2 mRNA expression is nearly undetectable in the VMH (Luo et al., 1994; Sackovsky et al., 1995; Shinoda et al., 1995), suggesting CRF2 is expressed in SF1 cells in the VMH. Consistent with this notion, it was found that more than 90% of CRF2 neurons in the dorsomedial part of the nucleus are also SF1-positive (Figure 2) with less colocalization of these two materials in the VMHVd (Digruccio et al., 2007).

CRF Ligands Input into the VMH

The anatomical distribution of a number of the CRF family peptides has been determined, and it was found that CRF and Ucn1-expressing neurons provide minor innervation to the VMH (Swanson et al., 1983; Kozicz et al., 1998; Bittencourt et al., 1999). Interestingly, low levels of Ucn1-immunoreactivity have been detected in cells in the VMH (Kozicz et al., 1998), suggesting Ucn1 may be a local factor in the nucleus. Although Ucn2 fiber distribution has not been determined, Ucn2-positive cells have been found in a number of brain areas including the magnocellular part of the PVH, locus ceruleus, and facial motor nucleus (Reyes et al., 2001), and none of these areas provide extensive projection into the VMH (Reyes et al., 2001), and none of these areas provide extensive projection into the VMH (Reyes et al., 2001). Compared to other CRF innervations, Ucn3 neuronal fibers abundantly innervate the VMH (Li et al., 2002). Similar to the expression of CRF2 in the VMH, Ucn3-positive axonal fibers and terminals concentrate in the dorsomedial part of the VMH with reduced density toward the ventrolateral part of the nucleus (Li et al., 2002). As stated above, Ucn3 neurons in the PVN provide the major Ucn3 afferent input into the VMH and Ucn3 cells in the pBNST and

FIGURE 2 | (A) Darkfield photomicrograph showing CRFRII mRNA signal revealed by in situ hybridization in the basal hypothalamic area of a transgenic mouse expressing Cre recombinase (Cre) and enhanced yellow fluorescent protein (EYFP) in SF1-positive cells. Note that CRFRII mRNA hybridization signal (white clusters) was abundant in the dorsomedial part of the VMH (VMHdm). (B) Bright field photomicrograph of the same area in (A) showing SF1-positive cells, revealed by immunostaining with anti-green fluorescent protein antibody (darkbrown precipitates) in the VMH. (C) High magnification of boxed area in (A) showing colocalization of CRFRII (black dot clusters) and SF1 (brown precipitates) in the VMH. ARH, arcuate nucleus of hypothalamus; V3, third ventricle; VMHc, central part of the VMH; VMHdm, dorsomedial part of the VMH; VMHvl, ventrolateral part of the VMH. Scale bar = 50 μm (B), 20 μm (C).
the MeA comparatively provide moderate input into the nucleus (Chen et al., 2011). Interestingly, Ucn 3 cells in the rPFH, immediately rostral and adjacent to the PVH, provide minimal Ucn 3 afferent input into the VMH and instead send strong innervation into the LS.

Neural inputs into the PVHap and MeA have been studied (Sawchenko and Swanson, 1983; Swanson and Petrovich, 1998; Uehara et al., 1998; Maras and Petruska, 2010; Carrillo et al., 2011; Northcutt and Lonstein, 2011; Radelly and Sawchenko, 2011; Van Hovers et al., 2011). In general, the two brain areas receive similar afferent input from a number of brain regions including the septal nuclei and amygdala. However, a few subtle but significant exceptions should be noted. The PVHap receives prominent inputs from the hypothalamus, cortex, and brainstem, whereas the MeA receives strong inputs from the bed nucleus of the accessory olfactory tract and nucleus of stria medullaris. These findings suggest Ucn 3 cells in the PVHap receive inputs that transmit visceral and autonomic information while the Ucn 3 cell group in the MeA receives afferents that relay olfactory information. Thus, it is conceivable that central Ucn 3 may serve as a common peptide neurotransmitter in the various neural pathways that convey information from assorted neural signals into the VMH to coordinate the regulation of energy homeostasis.

**FUNCTION OF CRF2 IN THE VMH**

When the function of CRF2 in the VMH was first assessed by injecting Ucn 1 into the VMH, it was found that the peptide potently suppresses food intake (Ohata et al., 2000). However, because CRF2 has been suggested to be expressed in the VMH (Cheng et al., 2007) and Ucn 1 has equally high affinity for both CRF2 and CRF1 (Vaughan et al., 1995), it remains possible that CRF2 may also contribute to the anorectic effect of Ucn 1 in the VMH. More recently, when the CRF2-selective ligand Ucn 3 was identified (Lewis et al., 2001), the function of CRF2 in the VMH was re-examined by site-specific injection of Ucn 3 into the VMH (Fekete et al., 2007; Chen et al., 2010). Consistent with the Ucn 1 injection study, stimulation of CRF2 by Ucn 3 in the VMH significantly suppresses feeding. Moreover, stimulation of CRF2 in other regions including the PVH, amygdala, and the lateral hypothalamus fails to modulate feeding (Ohata et al., 2000; Fekete et al., 2007; Chen et al., 2010), reinforcing the notion that VMH CRF2 plays a critical role in mediating the effect of CRF peptides in suppressing food intake.

In addition to appetite suppression, activation of CRF2 in the VMH results in rapid elevation of blood glucose levels (Chen et al., 2010). This is consistent with the function of VMH neurons in glucose homeostasis, as VMH neurons have been suggested to play an important role in regulating glucose levels via gluconeogenesis, and modulating glucose production in peripheral tissues (Kang et al., 2004; Levin et al., 2004). On the other hand, it has been shown that stimulation of CRF2 in the VMH suppresses insulin-induced release of glucagon and epinephrine (McCrimmon et al., 2006), indicating that VMH CRF2 exerts a negative control over the counterregulatory response (CR). Taken together, it is possible that the functional role of CRF2 in the VMH in glucose homeostasis is context dependent. When blood glucose is low as a result of hyperinsulinemia, CRF2 in the VMH negatively regulates the CRF2 receptor. On the other hand, under normoglycemia, CRF2 induces acute hyperglycemia to facilitate fuel mobilization perhaps in response to stress. We have also found that CRF2-positive neurons in the VMH are sensitive to glucose, as high glucose inhibits and low glucose stimulates the neuronal activity (Digruccio et al., 2007).

Type 2 CRF receptor has been shown to modulate the HPA axis. For example, CRF2 KO mice display altered HPA hormonal secretion, and central Ucn 3 injection facilitates stress-induced ACTH secretion (Simmion et al., 2006). On the other hand, activation of CRF2 in the VMH fails to modulate HPA hormone secretion (Chen et al., 2010), indicating that the receptor in the VMH is not essential for central Ucn 3-induced HPA activation. Thus, CRF2-positive brain areas that are important for modulation of the HPA axis remain to be determined.

**PHYSIOLOGICAL ROLE OF CRF2 IN THE VMH**

To probe the physiological role of endogenous CRF2 in the VMH, VMH-specific CRF2 knockdown mice were generated by injection of a lentiviral vector expressing CRF2 small hairpin RNA (shRNA; Chao et al., 2012). Mice injected with CRF2 shRNA displayed significantly reduced CRF2 mRNA levels and gain more weight, mostly in white fat, than control mice. Furthermore, similar to Ucn 3 null mice, mice with reduced CRFR2 in the VMH exhibited elevated basal food intake and ate more than the control mice after overnight fasting. This result indicates that CRF2 in the VMH serves as a brake to facilitate the cessation of feeding. This study suggests that CRF2 in the VMH plays a critical role in mediating the effect of central Ucn 3 in energy balance.

In addition to elevated feeding, mice with decreased expression of CRF2 in the VMH display reduced lipolysis and increased adiposity in white fat (Chao et al., 2012). This is likely due to reduced SNS activity, as the VMH has been shown to regulate lipolysis via sympathetic outflow (Kamson et al., 1976; Takahashi and Shimizu, 1981; Ruffin and Nicolaidis, 1999). Interestingly, CRF2 knockdown in the VMH has no major impact in heat production or uncoupling protein 1 expression in BAT, suggesting that CRF2 in the VMH does not significantly modulate thermogenesis in BAT. This result appears to disagree with earlier reports that VMH is involved in regulating thermogenesis in BAT (Perkins et al., 1981; Kim et al., 2011). Anatomical studies have demonstrated a compartment-specific organization of innervation of different peripheral organs, as abdominal fat and subcutaneous fat are innervated by different neural pathways (Kreier et al., 2002, 2006). It is possible that CRF2-positive neurons are a subpopulation of cells in the VMH that regulate SNS outflow to white fat without significant functional impact on BAT. Heterogeneity of VMH neurons has been reported as overlapping but distinct subpopulation of neurons in the VMH that are critical in regulating fighting and mating (Lin et al., 2011).

Consistent with the function of CRF2 in regulating blood glucose levels, mice with reduced CRF2 expression in the VMH show improved glucose homeostasis compared to control mice (Chao et al., 2012). Moreover, mice with CRF2 knocked down in the VMH exhibit an exaggerated rebound in blood glucose levels compared to control mice after the initial hypoglycemic response to insulin challenge. This result agrees with the study by McCrimmon et al.
Chen et al. Central CRF2 in energy homeostasis

(2006), who found that injection of Ucn 3 into the VMH suppresses the hypoglycemia-induced CRR response. Taken together, these studies strongly argue that CRF2 is a critical molecular mediator in VMH regulation of glucose homeostasis.

NEUROCIRCUITS UNDERLYING THE EFFECT OF VMH

To understand how VMH CRF2 neurons regulate output functions and to describe an anatomical link between these neurons and the SNS, it is necessary to determine their axonal projections to identify downstream targets in the brain. A number of anterograde tracing studies utilizing different tracers have been performed to evaluate the projections of VMH neurons. Generally, it was found that VMH neurons project extensively to neighboring hypothalamic nuclei including the anterior and paraventricular nucleus, BNST, and periaqueductal gray (PAG; Saper et al., 1976; Canteras et al., 1994). These anatomical studies raise an interesting dilemma. Although it is clear that VMH activity modulates SNS activity, these studies failed to observe direct VMH efferents within well-known autonomic centers in the brainstem. Thus, it was concluded that the VMH likely modulates SNS activity indirectly by first projecting to a relay center such as the PAG.

Recently, using a conditional viral tracing approach, we have found that VMH neurons project to a number of important brainstem autonomic centers including the parabrachial nucleus, C1 catecholaminergic cell group in the rostral ventrolateral medulla, and the nucleus of solitary tract (Lindberg et al., 2011). Moreover, we have used the same approach to find that CRF2-positive cells in the VMH show similar axonal projections to these brainstem areas (Figure 3; Lindberg et al., 2011). These studies demonstrate that VMH neurons, including cells that express CRF2, can potentially modulate SNS activity by direct projections to brainstem autonomic centers.

CONCLUSION

The function of CRF peptides and their receptors in coordinating hormonal, neuronal, and behavioral responses to stress is well recognized. Pharmacological studies have determined that the CRF2 receptors are involved in the regulation of energy homeostasis. Recent studies using various genetic mouse models and molecular tools have further ascertained the critical role of CRF2 and its selective ligands, including Ucn 3, in feeding, blood glucose regulation, SNS output, and peripheral metabolism. Moreover, CRF2 in the VMH mediates most, if not all, of the effects of central Ucn 3 on energy homeostasis.

It is clear that conflicting results have been observed between whole body and region- or tissue-specific KO or overexpression mouse models. Furthermore, several studies have demonstrated that anatomical or even functional heterogeneity exists within a seemingly single Ucn 3 cell population in the hypothalamus. Thus, a more detailed understanding of the physiological function of CRF2 and its selective ligands in the brain will be aided by brain region-specific transgenic animal models permitting manipulation of ligand or receptor expression. Study of such models will provide insight into the specific roles of CRF2 in modulating metabolic functions.

Regulation of energy balance under diverse challenges including stress, starvation, or high-fat diet requires numerous adaptive mechanisms in both central and peripheral tissues. It is now clear that central CRF2 and Ucn 3 are involved in this regulation, as the expression of the receptor and ligands are closely regulated under these challenges. It is thus conceivable that dysregulated CRF2 or ligand function potentially cause or exacerbate metabolic perturbations. This hypothesis can be easily tested with the above mentioned rodent models to determine the functional role of the CRF2 system in metabolic diseases. Moreover, a better understanding of the molecular mechanisms by which various
This text is a natural representation of the document as if you were reading it.
The expression of vascular gluta-
mate transporters defines two classes of
enzymatic loops. Nature 31, 247–260.

Gardner, J. D., Rothwell, N. J.,
and Luheshi, G. N. (1998). Leptin
sensitivity and protection against noise-
induced hearing loss. Neuronal. 86, 260–268.

Grammatopoulos, D. K. (2010).
Urocortin, but not corticotropin-
releasing hormone (CRH), activates the
mitogen-activated protein kinase signal
transduction pathway in human preg-
nant myometrium: an effect mediated via R1 and R2 CRH
receptor subtypes and stimulation of
Gq proteins. Mol. Endocrinol. 14, 2074–2085.

Gurdjian, E. S. (1927). The dien-
siveness of mice deficient in
corticoids. Proc. Natl. Acad. Sci. U.S.A.
92, 198–206.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.

Jamieson, P. M., Cleftly, M. E., Kaper-
man, Y., Morton, N. M., Kelly, F. A., Bowerman, D. G., et al. (2011).
Urocortin 3 transgenic mice exhibit a metabolically favorable phenotype
improving obesity on a high fat diet. Diabetesologia 54, 2392–2405.

Kang, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 247–260.

King, J. G. (1997). Corticotropin-
releasing factor-like peptides increase
cytosolic Ca2+ in rat pancreatic beta-cells. Diabetologia 40, 757–764.

Kung, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 34, 907–910.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.

Jamieson, P. M., Cleftly, M. E., Kaper-
man, Y., Morton, N. M., Kelly, F. A., Bowerman, D. G., et al. (2011).
Urocortin 3 transgenic mice exhibit a metabolically favorable phenotype
improving obesity on a high fat diet. Diabetesologia 54, 2392–2405.

Kang, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 247–260.

Kung, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 34, 907–910.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.

Jamieson, P. M., Cleftly, M. E., Kaper-
man, Y., Morton, N. M., Kelly, F. A., Bowerman, D. G., et al. (2011).
Urocortin 3 transgenic mice exhibit a metabolically favorable phenotype
improving obesity on a high fat diet. Diabetesologia 54, 2392–2405.

Kang, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 247–260.

Kung, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 34, 907–910.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.

Jamieson, P. M., Cleftly, M. E., Kaper-
man, Y., Morton, N. M., Kelly, F. A., Bowerman, D. G., et al. (2011).
Urocortin 3 transgenic mice exhibit a metabolically favorable phenotype
improving obesity on a high fat diet. Diabetesologia 54, 2392–2405.

Kang, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 247–260.

Kung, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 34, 907–910.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.

Jamieson, P. M., Cleftly, M. E., Kaper-
man, Y., Morton, N. M., Kelly, F. A., Bowerman, D. G., et al. (2011).
Urocortin 3 transgenic mice exhibit a metabolically favorable phenotype
improving obesity on a high fat diet. Diabetesologia 54, 2392–2405.

Kang, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 247–260.

Kung, L., Routb, V. H., Kusuhara-
dahl, E. V., Gardas, L. D., and Levin, R. E. (2004). Physiological and
molecular characteristics of rat hypothalamic somatostatin receptor
subtypes. J. Neurosci. 34, 907–910.

Inoue, S., Campfield, L. A., and Bray, G. A. (1977). Comparison of metabolic
alterations in hypothalamic and high fat diet-induced obesity. Am. J. Phys-
iol. 235, E62–E68.
of thermogenesis in mammals. Exp. Physiol. 95, 773–779.

Mousant, S., Chen, W., Piffl, D. W., Kaplink, M. G., and Ogawa, S. (2016). RNase mediated silencing of estrogen receptor (alpha) in the ventromedial nucleus of hypothalamic ablation female sexual behaviors. Proc. Natl. Acad. Sci. U.S.A. 113, 10456–10461.

Mousant, S., Chen, W., Piffl, D. W., Mobius, C. V., Yang, X. J., Clegg, D. J., et al. (2007). Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamic leads to metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 113, 2051–2056.

Nakamura, A., Bevan-Jannaoud, F., and Jannemand, B. (1984). Role of ventromedial hypothalonsus in sympathetic effents of brown adipose tissue. Am. J. Physiol. 247, R535–R564.

Nishimura, M., Makino, S., Asahi, K., and Hashimoto, K. (1999). Lipin effects on the expression of type-2 CRH receptor mRNA in the rat. J. Neuroendocrinol. 11, 307–314.

Northcutt, K. C., and Leonard, J. S. (2011). Neurounatomical projcetions of the species-specific tyrosine hydroxylase-immunoreactive celis of the male prairie vole bed nucleus of the stria terminalis and medial amygdala. Brain Behav. Evol. 77, 177–192.

Okita, H., and Shibasaki, T. (2004). Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides 25, 1703–1709.

Okita, H., Suzuki, K., and Yoshi, K., and Shibasaki, T. (2000). Urocortin in the ventromedial hypothalamic nucleus acts as an inhibitor of feeding behavior in rats. Brain Res. 861, 1–7.

Parkes, K. L., Rice, D. A., Lala, D. S., Bock, L. A., Xi, Q., Yang, W., et al. (2002). Stereotaxic placement of an essential mediator of endocrine deafferentation affects food intake. Endocrinology 147, 59–56.

Pelleymounter, M. A., Johnson, A. D., Bessman, B., Murphy, B., et al. (2000). Role of corticotropin-releasing factor (CRF) receptors in the arcuate syndrome induced by CRF 1/2 [Epub: Exp.
that stimulates the secretion of corticotropin and β-endorphin. Science 213, 194–197.

Van Meter, C., Han, P., and Li, C. (2011). Stress-activated afferent inputs into the mediobasal hypothalamus: Implication of neuropeptides mediating stress-activation of Urocortin 3 neurons in the amygdala. Soc. Neurosci. Abstr. 37, 141.9.

Van Pett, K., Viana, V., Bitnercourt, J. C., Chan, K. W., Li, H.-Y., Arras, C., et al. (2008). Distribution of mRNA encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428, 181–212.

Vaughan, J. M., Donaldson, C., Bitnercourt, J., Perrin, M. H., Lewis, K., Sutton, S., et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Neuron 15, 287–292.

Venihaki, M., Sakihara, S., Subramanian, S., Dikkes, P., Wenseler, S. C., Liapakis, G., et al. (2004). Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J. Neuroendocrinol. 16, 411–422.

Vetter, D. E., Li, C., Zhao, L., Conforti, A., Liberman, M. C., Smith, G. W., et al. (2002). Urocortin-deficient mice show hearing impairment and increased anxiety-like behaviour. Nat. Genet. 31, 385–389.

Wang, C., and Kett, C. (2002). Urocortin III in the lateral septal area modulates feeding induced by oestradiol in the lateral hypothalamus. Am. J. Physiol. Endocrinol. Metab. 283, E865–E870.

Wiley, K. E., and Davisport, A. P. (2004). CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortin 2 and 3 are potent vasoconstrictors. Br. J. Pharmacol. 143, 508–514.

Wolfang, M., J., Cha, S. H., Sielhove, A., Cholman, S., Clune, G., Shulman, G. L., et al. (2007). Regulation of hypothalamic malonyl-CoA by central glucose and leptin. Proc. Natl. Acad. Sci. U.S.A. 104, 19289–19294.

Zaborszky, L. (1982). Afferent connections of the medial basal hypothalamus. Adv. Anat. Embryol. Cell Biol. 69, 1–117.

Zagars, J. R., Cullinan, W. E., and Herman, J. P. (2002). Distribution of vesicular glutamate transporter mRNAs in rat hypothalamus. J. Comp. Neurol. 446, 217–229.

Zigman, J. M. (2003). Minireview: from anorexia to obesity–the yin and yang of food weight control. Endocrinology 144, 3749–3756.